IK-930 (TEAD inhibitor) ✔️

Ikena Oncology

Note: Originally figured this one out on January 26, 2023 and posted on Twitter on February 6, 2023. Confirmed correct on March 6, 2023.

IK-930 is an oral transcriptional enhanced associate domain (TEAD) inhibitor developed by Ikena Oncology (IKNA 0.00%↑). It is currently being evaluated in phase 1 trials in advanced solid tumors with/without genetic mutations to the Hippo pathway (NCT05228015). TEADs are involved in cell proliferation, tissue homeostasis, and regeneration.

Detective work for this compound was done by request! Here’s a plug: if there’s a compound you might be interested in having me look at, subscribe & click the link at the bottom of this post for access to the suggestion link :)